September 23, 2019 Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope
August 27, 2019 Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity™ Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy
August 22, 2019 Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA
August 13, 2019 Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases
August 9, 2019 Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights